Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29467678 | 1.00 | GLP1R (0.43) | GLP1RHPGDHTTSMN1; SMN2TP53 | |
| SCHEMBL23451371 | 1.00 | GLP1R (0.43) | GLP1RHPGDHTTSMN1; SMN2TP53 | |
| SCHEMBL29467730 | 0.96 | GLP1R (0.40) | GLP1RHPGDHTTSMN1; SMN2TP53 | |
| SCHEMBL29467590 | 0.96 | GLP1R (0.41) | GLP1RHPGDHTTSMN1; SMN2TP53 | |
| SCHEMBL30408933 | 0.95 | GLP1R (0.40) | GLP1RHPGDHTTSMN1; SMN2TP53 | |
| SCHEMBL30407159 | 0.95 | GLP1R (0.43) | GLP1RHPGDHTTSMN1; SMN2TP53 | |
| SCHEMBL25686533 | 0.94 | GLP1R (0.42) | GLP1RHPGDHTTSMN1; SMN2TP53 | |
| SCHEMBL25682703 | 0.93 | GLP1R (0.41) | GLP1RHPGDHTTSMN1; SMN2TP53 | |
| SCHEMBL29467675 | 0.91 | GLP1R (0.39) | GLP1RHPGDHTTSMN1; SMN2ROCK2 | |
| SCHEMBL29467571 | 0.91 | HPGD (0.45) | GLP1RHPGDHTTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| US-20210169896-A1 | A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | FCGR2A, FCGR3B, FCGR1A | GLP1R 2116/4885HPGD 3598/4885HTT 2413/4885 |
| US-20210169896-A1 | A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | PBDC1, BRD2, CD79B | GLP1R 4709/4885HPGD 1151/4885HTT 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.